← Leaderboards
Keith L Ligon
Brigham And Women'S Hospital
$15,402,631
Attributed
$24,388,751
Total exposure
16
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,388,751 · 16
By mechanism
R01$16,817,496 · 5
P50$3,604,314 · 6
P01$3,091,061 · 4
K08$875,880 · 1
Top collaborators
- Rameen Beroukhim24 shared
- Arnab Chakravarti5 shared
- Scott R Manalis4 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorGenomicsTissuesGliomaResistanceClinical TrialsTargeted TreatmentMutationResponseCell LineGlioblastomaSamplingInnovationBaseCellsMalignant NeoplasmsProgramsMutantImmunohistochemistryPathway InteractionsNeoplastic CellNeuropathologyEnsureBiobank
Grant awards (59)
Evolution of gliomas during treatment and resistance$697,603
R01 · FY2025 · CA
Synthetic lethalities to cell cycle disruption in glioma$673,491
R01 · FY2025 · CA
Core 1: Pathology Core$347,213
P50 · FY2025 · CA · contact PI
Core 2: Glioblastoma Biorepository Core$133,022
P01 · FY2025 · CA · contact PI
Evolution of gliomas during treatment and resistance$662,723
R01 · FY2024 · CA
Synthetic lethalities to cell cycle disruption in glioma$639,818
R01 · FY2024 · CA
Core 1: Pathology Core$372,800
P50 · FY2024 · CA · contact PI
Core 2: Glioblastoma Biorepository Core$126,370
P01 · FY2024 · CA · contact PI
Evolution of gliomas during treatment and resistance$683,652
R01 · FY2023 · CA
Synthetic lethalities to cell cycle disruption in glioma$660,022
R01 · FY2023 · CA
Pathology - Core A$316,376
P50 · FY2023 · CA · contact PI
Core 2: Glioblastoma Biorepository Core$152,772
P01 · FY2023 · CA · contact PI
Evolution of gliomas during treatment and resistance$683,652
R01 · FY2022 · CA
Synthetic lethalities to cell cycle disruption in glioma$668,921
R01 · FY2022 · CA
Pathology - Core A$316,375
P50 · FY2022 · CA · contact PI
Core 2: Glioblastoma Biorepository Core$169,138
P01 · FY2022 · CA · contact PI
Evolution of gliomas during treatment and resistance$736,601
R01 · FY2021 · CA
MYB family alterations in pediatric gliomas$554,504
R01 · FY2021 · CA · contact PI
Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine Gliomas$523,271
R01 · FY2021 · CA
Pathology - Core A$295,939
P50 · FY2021 · CA · contact PI
Core 2: Glioblastoma Biorepository Core$172,590
P01 · FY2021 · CA · contact PI
MYB family alterations in pediatric gliomas$554,504
R01 · FY2020 · CA · contact PI
Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine Gliomas$517,874
R01 · FY2020 · CA
Pathology - Core A$301,106
P50 · FY2020 · CA · contact PI
Core 2: Glioblastoma Biorepository Core$172,590
P01 · FY2020 · CA · contact PI
Genetic evolution of glioblastomas during radiation and temozolomide therapy$656,695
R01 · FY2019 · CA
MYB family alterations in pediatric gliomas$537,868
R01 · FY2019 · CA · contact PI
Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine Gliomas$497,259
R01 · FY2019 · CA
Pathology - Core A$355,881
P50 · FY2019 · CA · contact PI
Core 2: Glioblastoma Biorepository Core$167,412
P01 · FY2019 · CA · contact PI
Genetic evolution of glioblastomas during radiation and temozolomide therapy$682,620
R01 · FY2018 · CA
MYB family alterations in pediatric gliomas$554,504
R01 · FY2018 · CA · contact PI
Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine Gliomas$507,552
R01 · FY2018 · CA
Core 2: Glioblastoma Biorepository Core$192,342
P01 · FY2018 · CA · contact PI
Genetic evolution of glioblastomas during radiation and temozolomide therapy$689,449
R01 · FY2017 · CA
MYB family alterations in pediatric gliomas$554,504
R01 · FY2017 · CA · contact PI
Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine Gliomas$502,615
R01 · FY2017 · CA
Pathology Core$355,741
P50 · FY2017 · CA · contact PI
Genetic evolution of glioblastomas during radiation and temozolomide therapy$697,496
R01 · FY2016 · CA
Pathology Core$342,427
P50 · FY2016 · CA · contact PI
Genetic evolution of glioblastomas during radiation and temozolomide therapy$704,210
R01 · FY2015 · CA
Assaying GBM growth and therapy response in single cells and tumorspheres (PQ17)$489,889
R01 · FY2015 · CA · contact PI
Shared Resources Core$322,920
P01 · FY2015 · CA · contact PI
Pathology Core$98,306
P50 · FY2015 · CA · contact PI
Assaying GBM growth and therapy response in single cells and tumorspheres (PQ17)$487,338
R01 · FY2014 · CA · contact PI
Shared Resources Core$313,547
P01 · FY2014 · CA · contact PI
Pathology Core$155,602
P50 · FY2014 · CA · contact PI
Assaying GBM growth and therapy response in single cells and tumorspheres (PQ17)$486,240
R01 · FY2013 · CA · contact PI
Pathology Core$346,548
P50 · FY2013 · CA · contact PI
Shared Resources Core$301,946
P01 · FY2013 · CA · contact PI
Assaying GBM growth and therapy response in single cells and tumorspheres (PQ17)$512,621
R01 · FY2012 · CA · contact PI
Shared Resources Core$331,121
P01 · FY2012 · CA · contact PI
Neuropathology Core$195,487
P01 · FY2012 · CA · contact PI
Shared Resources Core$339,804
P01 · FY2011 · CA · contact PI
Olig function in CNS development and tumorigenesis$175,176
K08 · FY2008 · NS · contact PI
Olig function in CNS development and tumorigenesis$175,176
K08 · FY2007 · NS · contact PI
Olig function in CNS development and tumorigenesis$175,176
K08 · FY2006 · NS · contact PI
Olig function in CNS development and tumorigenesis$175,176
K08 · FY2005 · NS
Olig function in CNS development and tumorigenesis$175,176
K08 · FY2004 · NS